Norway· NO-ID_3D86B26F-8192-4987-97A7-5163637A1170
Elrexfio
A elranatamab product containing elranatamab, registered in Norway by Pfizer Europe MA EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Elranatamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX32 (elranatamab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Elranatamab · ATC L01FX32
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Elranatamab
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Norway (NO)
- ATC code
- L01FX32
- ATC class
- Elranatamab
- Defined daily dose
- 5.43 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_3D86B26F-8192-4987-97A7-5163637A1170
- no_varenummer4578561.1NOK 43855
- no_varenummer5313771.9NOK 75758.1
- gtin5415062113189
- gtin5415062113196
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elranatamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElrexfio 40 mg/mlPfizer Europe MA
- SwitzerlandElrexfio
- CzechiaELREXFIOPfizer Europe MA EEIG, Bruxelles
- SpainELREXFIO 40 MG/ML SOLUCION INYECTABLEPfizer Europe Ma Eeig
- IcelandElrexfioPfizer Europe MA EEIG*
- PolandElrexfioPfizer Europe MA EEIG
- SwedenELREXFIO 40 mg/ml Injektionsvätska, lösningPfizer Europe MA EEIG
- United StatesElrexfioU.S. Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Elrexfio
- Liechtenstein · Elrexfio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4e48b396-802e-4107-ad75-3f6b9e6fdb47 GET /v1/drugs/4e48b396-802e-4107-ad75-3f6b9e6fdb47?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Elranatamab",
"merkevare_id": "ID_3D86B26F-8192-4987-97A7-5163637A1170",
"name_form_strength": "Elrexfio inj, oppl 40 mg/ml",
"prescription_group": "C"
}See everything about elranatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.